Lyell Immunopharma (LYEL) Return on Capital Employed (2021 - 2026)
Lyell Immunopharma (LYEL) reported Return on Capital Employed of 83.11% for Q1 2026, up 293.0% on a YoY basis from 21.15% in Q1 2025, and little changed sequentially from 83.0% in Q4 2025.
Lyell Immunopharma (LYEL) Return on Capital Employed (2021 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 6 years of Return on Capital Employed data on file, last reported at 83.11% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 293.0% year-over-year to 83.11%; the trailing twelve-month figure through Mar 2026 stood at 83.11% (up 293.0% YoY), and the FY2025 full-year result was 73.6%, down 1029.0% from the prior year.
- Return on Capital Employed was little changed at 83.11% in Q1 2026, from 83.0% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 20.32% in Q2 2022 to a low of 96.07% in Q2 2025.
- A 5-year average of 47.68% and a median of 34.8% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed plunged 6099 bps in 2025 and soared 293 bps in 2026, its largest moves.
- Tracing LYEL's Return on Capital Employed over 5 years: stood at 20.32% in 2022, then sank by 65 bps to 33.47% in 2023, then plunged by 114 bps to 71.57% in 2024, then decreased by 16 bps to 83.0% in 2025, then retreated by 0 bps to 83.11% in 2026.
- Business Quant data shows LYEL's Return on Capital Employed at 83.11% in Q1 2026, 83.0% in Q4 2025, and 93.99% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Lyell Immunopharma | 298.14 Mn | 298.14 Mn | - | -83.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83.11% |
| Dec 31, 2025 | -83.00% |
| Sep 30, 2025 | -93.99% |
| Jun 30, 2025 | -96.07% |
| Mar 31, 2025 | -86.04% |
| Dec 31, 2024 | -71.57% |
| Sep 30, 2024 | -36.00% |
| Jun 30, 2024 | -35.08% |
| Mar 31, 2024 | -34.80% |
| Dec 31, 2023 | -33.47% |
| Sep 30, 2023 | -25.93% |
| Jun 30, 2023 | -25.46% |
| Mar 31, 2023 | -20.61% |
| Dec 31, 2022 | -20.32% |
| Sep 30, 2022 | -23.18% |
| Jun 30, 2022 | -20.32% |
| Mar 31, 2022 | -21.53% |
| Dec 31, 2021 | -19.24% |
| Sep 30, 2021 | -17.90% |